Related Experiment Video
Updated: Jul 25, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
[Langerhans cell histiocytoses: 50 years to histiocytosis X]
1Medizinische Universitäts-Kinderklinik, Inselspital Bern.
Insights
Histiocytosis X, now known as Langerhans cell histiocytosis, presents diverse behaviors from self-healing skin conditions to malignant systemic disease. Accurate histopathologic diagnosis and staging are crucial for appropriate treatment strategies.
Area of Science:
- Oncology
- Dermatology
- Pathology
Background:
- Histiocytoses are a diverse group of disorders characterized by an abnormal proliferation of histiocytes.
- These disorders range in biological behavior from indolent to overtly malignant.
- Langerhans cell histiocytosis (LCH), formerly Histiocytosis X, represents a significant subgroup with variable clinical presentations.
Purpose of the Study:
- To review the spectrum of Langerhans cell histiocytosis.
- To emphasize the importance of histopathologic diagnosis and staging for LCH.
- To discuss therapeutic approaches for LCH based on disease behavior.
Main Methods:
- Review of literature on histiocytoses, focusing on Langerhans cell histiocytosis.
- Analysis of clinical manifestations and biological behavior of LCH.
- Discussion of diagnostic and therapeutic guidelines.
Main Results:
- Langerhans cell histiocytosis exhibits a wide range of clinical manifestations, including self-healing cutaneous, benign solitary, and malignant systemic forms.
- Histopathologic diagnosis is mandatory for all histiocytic disorders, including LCH.
- Staging is essential for evaluating the need for therapy in LCH patients.
Conclusions:
- Langerhans cell histiocytosis requires precise histopathologic diagnosis and careful staging due to its variable clinical behavior.
- Treatment decisions for LCH should be guided by the extent and severity of the disease.
- Chemotherapy for malignant systemic LCH should adhere to established international protocols.
Abstract:
Histiocytoses encompass a heterogeneous group of histiocytic disorders that may be separated in a group of variable biological behaviour and in a clearly malignant group. The histopathologic diagnosis of all types of histiocytoses is always mandatory. The 50-year-old Histiocytosis X compiles a subgroup of different biological behaviour, nowadays called Langerhans cell histiocytoses--the subject of the review. It has a wide range of manifestations: self-healing cutaneous, benign solitary and malignant systemic manifestations require the staging in order to evaluate a possibly necessary therapy. Chemotherapy should be performed within international protocols.
